Fosun Pharma Announces Subsidiary's Acquisition of EU Drug GMP Certificate

5 day ago / Read about 0 minute

Author：小编

Fosun Pharma's holding subsidiary, Shanghai Henlius Biopharmaceuticals Co., Ltd., has successfully secured a Drug Good Manufacturing Practice (GMP) Certificate from Belgium. The certified products encompass Pertuzumab Injection and Denosumab Injection. The company has invested approximately RMB 235.82 million in the related production facilities. It is anticipated that global sales of these two medications will reach USD 3.322 billion and USD 7.462 billion, respectively, by 2024. While this certification does not immediately significantly impact Fosun Pharma's current financial performance, the potential future sales figures are promising. Nevertheless, definitive sales projections remain subject to uncertainty.

Previous page：'Guangdong Vehicles Southbound' Program Aiming for...

Next page：Wuhan University Launches School of Robotics, Join...

Return to List

Hot Reading

2 day ago

Journalists Just Roasted Sam Altman To His Face

2 day ago

Apple M5 Chip 2025: 5 Products Rumored to Get Upgrades Coming Later This Year

1 day ago

Companies That Tried to Save Money With AI Are Now Spending a Fortune Hiring People to Fix Its Mistakes

1 day ago

Bosses Are Using AI to Decide Who to Fire